Lenvatinib (Kisplyx)

Lenvatinib as a single agent and is available in the whole of the UK. Lenvatinib is indicated ‘in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF)-targeted therapy’ according to NICE. The combination is available in England but under review in Scotland. Lenvatinib with Pembrolizumab (Keytruda)  for untreated advanced renal cell carcinoma is in development and the expected NICE publication date is due in December 2022.

Delivery:  Capsule
Availability: UK